MedTrace Logo

Effects of Repetitive Transcrannial Magnetic Stimulation on Non-Suicidal Self-Injury

NCT06540300 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-08-06

No results posted yet for this study

Summary

Non-suicidal self-injury (NSSI) refers to a series of direct and consequently repeated injuries to one's body without suicidal intent. At present, it has become an important issue of mental disorders. This article focuses on the formation mechanism of NSSI and the intervention effect of rTMS on NSSI patients. At the same time, NSSI patients are collected, a treatment plan is designed to complete a two-week treatment, and the results are analyzed. The aim is to provide theoretical basis for the clinical diagnosis and treatment of NSSI, and also to provide reference for the clinical diagnosis and treatment of NSSI patients.

Conditions

  • NSSI

Interventions

OTHER

rTMS stimulation of right IPL

The stimulation site is the right IPL (EEG International 10-20 system, electrode CP4/CP6), with a stimulation frequency of 1-Hz and intensity of 100% RMT. There are 50 pulses each time, 20 seconds each cycle, 5 seconds each, with an interval of 15 seconds, for a total of 60 cycles, a total duration of 20 minutes, and a total of 3000 pulses. Perform treatment once a day, rest for 2 days after 5 consecutive days of treatment, for a total of 2 weeks, and receive 10 treatments.

Sponsors & Collaborators

  • Nanjing Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-30
Primary Completion
2025-05-30
Completion
2025-06-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06540300 on ClinicalTrials.gov